The city of Miami, Florida, currently has 5 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/20/2025
Locations: Local Institution - 0347, Miami, Florida +1 locations
Conditions: Progressive Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/19/2025
Locations: UHealth - University of Miami Health Systems, Miami, Florida
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/27/2025
Locations: Local Institution - 0401, Miami, Florida
Conditions: Idiopathic Pulmonary Fibrosis
Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/23/2025
Locations: Miami VA Health System, Miami, Florida
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Investigate Leramistat in Patients With IPF
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: Reliant Medical Research, Miami, Florida +1 locations
Conditions: Idiopathic Pulmonary Fibrosis